Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Molecular Profile Unknown unknown
Therapy Anlotinib
Indication/Tumor Type lung non-small cell carcinoma
Response Type not applicable


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown lung non-small cell carcinoma not applicable Anlotinib Clinical Study Actionable In a retrospective analysis, addition of Anlotinib (AL-3818) to chemotherapy resulted in a partial response (PR) in 27% (11/41) and stable disease (SD) in 51% (21/41) of patients with advanced non-small cell lung cancer, compared to PR in 15% (8/53) and SD in 36% (19/53) of patients treated with chemotherapy alone, disease control rate (78% vs 51%, p=0.007) and median progression-free survival (5.0 vs 3.5 months, p=0.002) were significantly improved (PMID: 32547218). 32547218
PubMed Id Reference Title Details
(32547218) A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. Full reference...